Arlington Capital Partners, a US-based private equity firm, has acquired Avian Vaccine Services business from Charles River Laboratories.

The terms of the transaction were not disclosed.

The new entity dubbed as AVS Bio will operate independently as a standalone platform for Arlington Capital Partners, and serve the biologic manufacturing and bioprocessing markets.

AVS Bio offers specific pathogen free (SPF) eggs, antigens, and cell products as well as adjacent laboratory products and services for the development and production of vaccines, therapeutics, and other biologics.

The Norwich, Connecticut-headquartered company also provides antibodies such as IgY for clinical trials, apart from diagnostic testing and manufacturing support services.

Mark Giragosian — Arlington Capital Partners Vice President said: “The combination of the Company’s strong market position, deep customer relationships, and unparalleled expertise in SPF products create an ideal foundation on which to build a new bioprocessing platform.”

AVS Bio employs approximately 250 people and operates more than 20 plants across the US and Europe.

Deb Tosto — AVS Bio President said: “We are very excited to be partnering with Arlington to grow AVS Bio as a standalone entity.

“Arlington’s deep pharma services expertise, as well as its ability to provide extensive strategic and capital support, will help AVS Bio thrive as we look to optimize our current offerings and develop new capabilities to better serve our customers.”

AVS Bio operated as a subsidiary of Charles River Laboratories before it was acquired by Arlington Capital Partners.

  Arlington Capital Partners, Avian Vaccine Services, AVS Bio, Charles River Laboratories, Connecticut, Deb Tosto, Mark Giragosian, Norwich, USA